PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
6.15
-0.14 (-2.23%)
At close: Mar 12, 2026, 4:00 PM EDT
6.13
-0.02 (-0.33%)
After-hours: Mar 12, 2026, 6:42 PM EDT
PepGen Employees
PepGen had 57 employees as of September 30, 2025. The number of employees decreased by 19 or -25.00% compared to the same quarter last year.
Employees
57
Change
-19
Growth
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,572,895
Market Cap
425.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 57 | -19 | -25.00% |
| Jun 30, 2025 | 62 | -10 | -13.89% |
| Mar 31, 2025 | 79 | 14 | 21.54% |
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Sep 30, 2024 | 76 | 13 | 20.63% |
| Jun 30, 2024 | 72 | 18 | 33.33% |
| Mar 31, 2024 | 65 | 16 | 32.65% |
| Dec 31, 2023 | 64 | 19 | 42.22% |
| Sep 30, 2023 | 63 | 23 | 57.50% |
| Jun 30, 2023 | 54 | 18 | 50.00% |
| Mar 31, 2023 | 49 | 18 | 58.06% |
| Dec 31, 2022 | 45 | 14 | 45.16% |
| Sep 30, 2022 | 40 | 17 | 73.91% |
| Jun 30, 2022 | 36 | 24 | 200.00% |
| Mar 31, 2022 | 31 | 19 | 158.33% |
| Dec 31, 2021 | 31 | - | - |
| Sep 30, 2021 | 23 | - | - |
| Jun 30, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 650 |
| Sutro Biopharma | 178 |
| Niagen Bioscience | 117 |
| Armata Pharmaceuticals | 60 |
| Shattuck Labs | 44 |
| Anavex Life Sciences | 34 |
| DiaMedica Therapeutics | 28 |
| vTv Therapeutics | 23 |
PEPG News
- 7 days ago - PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 8 days ago - US FDA puts partial clinical hold on PepGen's muscle disease drug trial - Reuters
- 8 days ago - PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights - Business Wire
- 8 days ago - PepGen Announces Regulatory Updates on FREEDOM2 - Business Wire
- 9 days ago - PepGen to Participate in the Leerink Global Healthcare Conference - Business Wire
- 3 months ago - PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer - Business Wire
- 3 months ago - PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - Business Wire
- 4 months ago - PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule - Business Wire